Eric Stonestreet, who played Cam on the ABC sitcom, said that he has slimmed down substantially while taking the GLP-1 ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

More dermatology patients are taking the popular drugs, but little is known about the biology of “Ozempic face” or how best ...

Losing even a moderate amount of weight is associated with reduced progression of diabetes, improved blood pressure and HDL ...

Though retrospective, the findings provide ‘compelling’ evidence that GLP-1 receptor agonists may help prevent development ...

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.

A decision is expected in the fourth quarter of 2025.

The WHO announced its plan to support GLP-1 weight-loss drugs, like Wegovy and Zepbound, to address the global obesity epidemic, according to Reuters.